Hosted on MSN
Contrarius Global Equity Fund’s thoughts on CRISPR Therapeutics’ (CRSP) gene editing therapy
Contrarius Investment Management, an investment management company, released its third-quarter investor letter for the “Contrarius Global Equity Fund”. A copy of the letter can be downloaded here. The ...
CRISPR Therapeutics AG is commercially validated with CASGEVY but remains financially unproven and operates at a loss despite strong cash reserves. Incremental buying is attractive now for patient ...
We expect CRISPR Therapeutics CRSP to surpass expectations when it reports fourth-quarter and full-year 2025 results. The company’s earnings beat estimates by 11.36% in the last reported quarter. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results